Effect of hypolipidemic treatment on glycemic profile in patients with mixed dyslipidemia

Table 2 Laboratory parameters at baseline and 3 mo later

	Baseline	3 mo	Percentage change
Fasting plasma glucose, mg/dL (mmol/L)
Switch to the highest dose rosuvastatin	91 ± 26 (5.1 ± 1.4)	95 ± 19 (5.3 ± 1.1)	4%b
Add-on-statin ER-NA/LRPT	93 ± 17 (5.2 ± 0.9)	102 ± 27 (5.7 ± 1.5)	10%bdf
Add-on-statin fenofibrate	94 ± 10 (5.2 ± 0.6)	94 ± 11 (5.2 ± 0.6)	0%
HbA1c, %
Switch to the highest dose rosuvastatin	6.1 ± 0.5	6.3 ± 0.5	0.2%b
Add-on-statin ER-NA/LRPT	6.3 ± 1.1	6.6 ± 1.2	0.3%bdf
Add-on-statin fenofibrate	6.1 ± 0.8	6.2 ± 1.0	0.10%
HOMA-IR index
Switch to the highest dose rosuvastatin	1.4 (1.2-2.1)	1.6 (1.5-2.6)	14%bf
Add-on-statin ER-NA/LRPT	1.5 (1.4-2.1)	2.5 (1.5-2.8)	65%bdf
Add-on-statin fenofibrate	1.7 (1.5-2.3)	1.6 (1.4-2.2)	-6%b

Values are expressed as mean ± SD [except for fasting plasma insulin and HOMA-IR index which are expressed as median (range)]. No significant differences in baseline data were found across groups.

^bP < 0.01 vs baseline;

^dP < 0.01 vs switch to the highest dose rosuvastatin group;

^fP < 0.01 vs add-on-statin fenofibrate group. ER-NA/LRPT: Extended release nicotinic acid/laropiprant; HOMA-IR index: Homeostasis model assessment of insulin resistance index; HbA1c: Glycosylated haemoglobin.